Disease or Syndrome – Talk Bio

Actionable Insights Powered by AI

IntraBio’s Levacetylleucine Succeeds in Phase 3 Trial for Ataxia-Telangiectasia, Plans FDA and EMA Approval

1 day ago talkbio0Tagged Approved, Ataxia Telangiectasia, Infrequent, IntraBio, levacetylleucine, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, Phase 3, United States Food and Drug Administration

IntraBio; levacetylleucine; Ataxia-Telangiectasia; Phase 3; FDA approval; EMA; rare disease

Novo Offloads Cell Therapy Technologies to Aspect After Retreat from the Field

1 day ago talkbio0Tagged Aspect - Kind of quantity, Cell Therapy, Diabetes Mellitus, Insulin-Dependent, Hypoimmune Technology, Novo Nordisk, stem cell-derived islet cells

Novo Nordisk; Aspect; cell therapy; type 1 diabetes; stem cell-derived islet cells; hypoimmune technology

Court Rejects HHS Motion to Dismiss Lawsuit Over US Childhood Vaccine Overhaul as Clinician Groups Push Forward

2 days ago talkbio0Tagged ACIP, antiarrhythmic peptide, Centers for Disease Control and Prevention (U.S.), CHARGE Syndrome, Childhood, Immunization Schedule, lawsuit, RFK gene, vaccine overhaul

childhood vaccine overhaul; HHS; lawsuit; ACIP; AAP; CDC; RFK Jr.; immunization schedule

Corvus Pharmaceuticals Reports Positive Phase 1 Data for Soquelitinib in Atopic Dermatitis, Exceeding Expectations

3 days ago talkbio0Tagged Corvus Pharmaceuticals, Dermatitis, Atopic, EASI, ITK gene, Phase 1 (qualifier value), soquelitinib

Corvus Pharmaceuticals; soquelitinib; Phase 1; atopic dermatitis; EASI reduction; ITK inhibitor

AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Trial of AAVB-081 for Usher Syndrome Type 1B-Associated Retinitis Pigmentosa

3 days ago talkbio0Tagged AAVantgarde, AAVB-081, Clinical Trials, gene therapy, LUCE-1, MYO7A gene, Retinitis Pigmentosa, Usher Syndrome Type 1B

AAVantgarde; LUCE-1; AAVB-081; Usher Syndrome Type 1B; USH1B; retinitis pigmentosa; gene therapy; clinical trial

Bayer and Vanderbilt University Medical Center Announce Five-Year Collaboration to Advance Cardiovascular and Kidney Disease Treatments

3 days ago talkbio0Tagged Bayer, BioVU, Cardiovascular Diseases, Collaboration, Kidney Diseases, Precision Medicine, Vanderbilt University Medical Center

Bayer; Vanderbilt University Medical Center; cardiovascular diseases; kidney diseases; collaboration; precision medicine; BioVU

FW In Conversation: Mineralys CEO Jon Congleton on Reviving Hypertension Innovation and Lorundrostat’s Best-in-Class Potential

4 days ago talkbio0Tagged aldosterone synthase inhibitor, conversation, For which was done, Hypertensive disease, Jon Congleton, Lorundrostat, Mineralys

Mineralys Therapeutics; Jon Congleton; lorundrostat; aldosterone synthase inhibitor; hypertension treatment; FW In Conversation

N.Y. Attorney General Sues Former Emergent BioSolutions CEO Robert Kramer for Insider Trading

4 days ago talkbio0Tagged AstraZeneca, COVID19 (disease), Emergent BioSolutions, insider, Letitia James, New York AG, Robert Kramer, stock sales, trading, Vaccines

insider trading; Emergent BioSolutions; Robert Kramer; New York AG; Letitia James; COVID-19 vaccine; AstraZeneca; stock sales

Caldera Therapeutics Launches with $112.5M Funding for China-Licensed IBD Bispecific Antibody

1 week ago talkbio0Tagged Antibodies, Bispecific, Caldera Therapeutics, CLD-423, Funding, Inflammatory Bowel Diseases, Qyuns Therapeutics

Caldera Therapeutics; IBD; bispecific antibody; $112.5M funding; Qyuns Therapeutics; CLD-423

Cityblock Health Appoints New CTO and Tech-Focused Board Members to Accelerate AI-Driven Care

1 week ago talkbio0Tagged Alberto Lopez Toledo, board members, Carboxyamidotriazole Orotate, Cityblock Health, Medicaid

Cityblock Health; CTO; Alberto Lopez Toledo; board members; AI; Medicaid